目的 探討欖香烯注射液聯(lián)合甲苯磺酸索拉非尼片治療肝癌的臨床療效。方法 選取2014年1月-2016年1月武警后勤學(xué)院附屬醫(yī)院收治的晚期原發(fā)性肝癌患者78例為研究對(duì)象，根據(jù)隨機(jī)區(qū)組設(shè)計(jì)法將患者分為對(duì)照組和治療組，每組各39例。對(duì)照組口服甲苯磺酸索拉非尼片，0.4 g/次，2次/d。治療組在對(duì)照組治療的基礎(chǔ)上靜脈滴注欖香烯注射液，0.6 g加入到5%葡萄糖溶液500 mL中，1次/d，連續(xù)使用21 d。以1個(gè)月為1個(gè)療程，兩組患者治療2個(gè)療程。觀察兩組的臨床療效，比較兩組的生活質(zhì)量改善情況、肝功能指標(biāo)、血清細(xì)胞因子、生存情況。結(jié)果 治療后，對(duì)照組和治療組的客觀緩解率（ORR）分別為38.5%、61.5%，臨床獲益率（DCR）分別為61.5%、82.1%，兩組比較差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組KPS評(píng)分、美國(guó)東部腫瘤協(xié)作組（ECOG）評(píng)分均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組卡氏評(píng)分（KPS評(píng)分）高于對(duì)照組，ECOG評(píng)分低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組丙氨酸氨基轉(zhuǎn)移酶（ALT）、天冬氨酸氨基轉(zhuǎn)氨酶（AST）、總膽紅素（TBIL）水平均顯著下降，白蛋白（ALB）水平顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組肝功能指標(biāo)明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清甲胎蛋白（AFP）、血管內(nèi)皮生長(zhǎng)因子（VEGF）水平均顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組血清細(xì)胞因子水平明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組中位生存期、1年生存率、2年生存率均顯著高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 欖香烯注射液聯(lián)合甲苯磺酸索拉非尼片治療肝癌具有較好的臨床療效，可改善患者肝功能，延長(zhǎng)生存期，提高生存質(zhì)量，安全較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Elemene Injection combined with Sorafenib Tosylate Tablets in treatment of liver cancer. Methods Patients (78 cases) with liver cancer in the Affiliated Hospital of Armed Police Logistics College from January 2014 to January 2016 were randomly divided into control and treatment groups, and each group had 39 cases. Patients in the control group were po administered with Sorafenib Tosylate Tablets, 0.4 mg/time, twice daily. Patients in the treatment group were iv administered with Elemene Injection on the basis of the control group, 0.6 g added into 5% glucose solution 500 mL, once daily, treated for 21 d. Patients in two groups were treated for 2 courses with 1 month as 1 course of treatment. After treatment, the clinical efficacies were evaluated, and the improvement of quality of life, liver function indexes, serum cytokines, and living condition in two groups were compared. Results After treatment, the ORR in the control and treatment groups were 38.5% and 61.5%, respectively, and there was difference between two groups (P<0.05). After treatment, the DCR in the control and treatment groups were 61.5% and 82.1%, respectively, and there was difference between two groups (P<0.05). After treatment, KPS scores and ECOG scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the KPS score in the treatment group was significantly higher than those in the control group, but the ECOG score in the treatment group was significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of ALT, AST, and TBIT in two groups were significantly decreased, but the levels of ALB in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the liver function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of AFP and VEGF in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum cytokines levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, median survival, 1 year survival rate, and 2 year survival rate in the treatment group were higher than those in the control group, and there was difference between two groups (P<0.05). Conclusion Elemene Injection combined with Sorafenib Tosylate Tablets has clinical curative effect in treatment of liver cancer, can improve the liver function, prolong the survival time, and improve the quality of life, with good safety, which has a certain clinical application value.